Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 5 von 44

Details

Autor(en) / Beteiligte
Titel
Fibrin sealant for esophageal anastomosis: A phase II study
Ist Teil von
  • World journal of gastrointestinal oncology, 2020-06, Vol.12 (6), p.651-662
Ort / Verlag
Baishideng Publishing Group Inc
Erscheinungsjahr
2020
Quelle
EZB Electronic Journals Library
Beschreibungen/Notizen
  • BACKGROUNDEsophagectomy is a pivotal curative modality for localized esophageal or esophagogastric junction cancer (EC or EJC). Postoperative anastomotic leakage (AL) remains problematic. The use of fibrin sealant (FS) may improve the strength of esophageal anastomosis and reduce the incidence of AL. AIMTo assess the efficacy and safety of applying FS to prevent AL in patients with EC or EJC. METHODSIn this single-arm, phase II trial (Clinicaltrial.gov identifier: NCT03529266), we recruited patients aged 18-80 years with resectable EC or EJC clinically staged as T1-4aN0-3M0. An open or minimally invasive McKeown esophagectomy was performed with a circular stapled anastomosis. After performing the anastomosis, 2.5 mL of porcine FS was applied circumferentially. The primary endpoint was the proportion of patients with AL within 3 mo. RESULTSFrom June 4, 2018, to December 29, 2018, 57 patients were enrolled. At the data cutoff date (June 30, 2019), three (5.3%) of the 57 patients had developed AL, including two (3.5%) with esophagogastric AL and one (1.8%) with gastric fistula. The incidence of anastomotic stricture and other major postoperative complications was 1.8% and 17.5%, respectively. The median time needed to resume oral feeding after operation was 8 d (Interquartile range: 7.0-9.0 d). No adverse events related to FS were recorded. No deaths occurred within 90 d after surgery. CONCLUSIONPerioperative sealing with porcine FS appears safe and may prevent AL after esophagectomy in patients with resectable EC or EJC. Further phase III studies are warranted.
Sprache
Englisch
Identifikatoren
ISSN: 1948-5204
eISSN: 1948-5204
DOI: 10.4251/wjgo.v12.i6.651
Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7340992
Format
Schlagworte
Clinical Trials Study

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX